Results 131 to 140 of about 160,145 (308)
Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy
, 2009 T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in childhood are recognized to be two different pathologies with different biological basis and are treated according to different pediatric ...
R. Rondelli +2 more
core +1 more source
British Journal of Haematology, EarlyView.In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz +4 more
wiley +1 more source
Lymphoblastic Erythrodermia [PDF]
Proceedings of the Royal Society of Medicine, 1927 openaire +2 more sources
British Journal of Haematology, EarlyView.Summary Comparative data on reduced‐dose (8 Gy) versus standard‐dose (12 Gy) total body irradiation (TBI) before allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for adults with acute lymphoblastic leukaemia (ALL) remain limited. We retrospectively analysed 101 adults undergoing first allo‐HSCT between 1999 and 2024 after 8 Gy or 12 Gy ...
Isabella Gruber +7 more
wiley +1 more source
Identification of downstream target genes of the t-cell oncoprotein HOX11 by global gene expression profiling [PDF]
, 2004 HOX11 is a homeodomain transcription factor that has been implicated in leukaemic transformation associated with T-cell acute lymphoblastic leukaemia (T-ALL).
Dixon, Darcelle Natalie
core
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients
, 2012 Michael E RyttingDepartment of Pediatrics and Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Asparaginase preparations deplete asparagine in acute lymphoblastic leukemia (ALL) blasts.
Rytting ME
core
Cell Proliferation, EarlyView.The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Guanheng Yang +8 more
wiley +1 more source
Hypergranular lymphoblastic leukaemia [PDF]
British Journal of Haematology, 2018 Inés Loyola +2 more
openaire +2 more sources